Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GB1211 |
Synonyms | |
Therapy Description |
GB1211 inhibits galectin-3 and facilitates the binding of anti-PD-1/PD-L1 antibodies to PD-1/PD-L1 respectively, potentially leading to decreased anti-PD-1/PD-L1 resistance (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2607-2607). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GB1211 | GB-1211|GB 1211 | GB1211 inhibits galectin-3 and facilitates the binding of anti-PD-1/PD-L1 antibodies to PD-1/PD-L1 respectively, potentially leading to decreased anti-PD-1/PD-L1 resistance (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2607-2607). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|